Cryo-Save India Private Limited, a wholly owned subsidiary of Cryo-Save, has instituted its state-of-the-art facility and R&D centre, slated to service India as well as the South-East Asia area in the near future, in Bangalore. The facility built in less than four months to operate from 7 key cities in India, has been granted all its licenses and the first sample storage have been completed by its highly motivated, well trained and customer oriented team.

Cryo-Save India, a pioneer in this sunrise sector, will be instrumental in contributing to the research and communication, with the ObGyn community, on the latest findings in the field, breakthrough procedures and technologies. The company, with its learnings from its European head office, has made inroads into the medical establishment with the objective of educating the Indian public on strides made in the in the stem cell segment in the Biotech sphere.

With the growing number of diabetics, cardio-vascular diseases and the emergence of new infectious diseases, the role of biotechnology will be crucial for countries like India with a population of over a billion people and with over 25 million births a year. India has emerged as one of the major countries involved in Stem Cell research. The Indian ministries of science & technology and health & family welfare propose to jointly promote extensive research in stem cells by leading academic and research institutions in the country.